10-Q 1 amtx_10q.htm QUARTERLY REPORT amtx_10q
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
———————
FORM 10-Q
———————
   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended: June 30, 2020
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the transition period from              to             
Commission File Number: 001-36475
———————
AEMETIS, INC.
 (Exact name of registrant as specified in its charter)
———————
Nevada
26-1407544
(State or other jurisdiction
(I.R.S. Employer
of incorporation or organization)
Identification No.)
20400 Stevens Creek Blvd., Suite 700
Cupertino, CA 95014
 (Address of Principal Executive Offices, including zip code)
(408) 213-0940
 (Registrant’s telephone number, including area code)
 
Title of each class of registered securities
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.001 par value
 
AMTX
 
NASDAQ
———————
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes  ☑ No ☐
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes   No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ Accelerated filer ☐   Non-accelerated filer ☐ Smaller reporting company ☑
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
 
The number of shares outstanding of the registrant’s Common Stock on July 31, 2020 was 20,795,891 shares.
 

 
 
 
AEMETIS, INC.
 
FORM 10-Q
 
Quarterly Period Ended June 30, 2020
 
INDEX
 
PART I--FINANCIAL INFORMATION
Item 1
Financial Statements.
4
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations.
34
Item 3.
Quantitative and Qualitative Disclosures about Market Risk.
46
Item 4.
Controls and Procedures.
46
PART II--OTHER INFORMATION
Item 1.
Legal Proceedings
47
Item 1A.
Risk Factors.
48
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
48
Item 3.
Defaults Upon Senior Securities.
48
Item 4.
Mine Safety Disclosures.
48
Item 5.
Other Information.
48
Item 6.
Exhibits.
49
Signatures
 
50
 
 
 
 
2
 
 
SPECIAL NOTE REGARDING FORWARD—LOOKING STATEMENTS
 
On one or more occasions, we may make forward-looking statements in this Quarterly Report on Form 10-Q, including statements regarding our assumptions, projections, expectations, targets, intentions or beliefs about future events or other statements that are not historical facts. Forward-looking statements in this Quarterly Report on Form 10-Q include, without limitation, statements regarding management’s plans; trends in market conditions with respect to prices for inputs for our products versus prices for our products; our ability to leverage approved feedstock pathways; our ability to leverage our location and infrastructure; our ability to incorporate lower-cost, non-food advanced biofuels feedstock at the Keyes plant; our ability to adopt value-add by-product processing systems; our ability to expand into alternative markets for biodiesel and its by-products, including continuing to expand our sales into international markets; our ability to maintain and expand strategic relationships with suppliers; our ability to continue to develop new and to maintain and protect new and existing intellectual property rights; our ability to adopt, develop and commercialize new technologies; our ability to refinance our senior debt on more commercial terms or at all; our ability to continue to fund operations and our future sources of liquidity and capital resources; our ability to sell additional notes under our EB-5 note program and our expectations regarding the release of funds from escrow under our EB-5 note program; our ability to improve margins; and our ability to raise additional capital. Words or phrases such as “anticipates,” “may,” “will,” “should,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “targets,” “will likely result,” “will continue” or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on current assumptions and predictions and are subject to numerous risks and uncertainties. Actual results or events could differ materially from those set forth or implied by such forward-looking statements and related assumptions due to certain factors, including, without limitation, the risks set forth under the caption “Risk Factors” below, which are incorporated herein by reference as well as those business risks and factors described elsewhere in this report and in our other filings with the Securities and Exchange Commission (the “SEC”), including without limitation, our most recent Annual Report on Form 10-K.
 
 
 
3
 
 
PART I - FINANCIAL INFORMATION
 
Item 1 - Financial Statements.
 
AEMETIS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In thousands except for par value)
 
 
 
June 30,
2020
 
 
December 31,
2019
 
Assets
 
(unaudited)
 
 
 
 
Current assets:
 
 
 
 
 
 
Cash and cash equivalents
 $3,410 
 $656 
Accounts receivable
  5,202 
  2,036 
Inventories
  7,290 
  6,518 
Prepaid expenses
  1,132 
  794 
Other current assets
  902 
  2,572 
Total current assets
  17,936 
  12,576 
 
    
    
Property, plant and equipment, net
  98,525 
  84,226 
Operating lease right-of-use assets
  2,906 
  557 
Other assets
  2,791 
  2,537 
Total assets
 $122,158 
 $99,896 
 
    
    
Liabilities and stockholders' deficit
    
    
Current liabilities:
    
    
Accounts payable
 $16,367 
 $15,968 
Current portion of long term debt
  7,569 
  5,792 
Short term borrowings
  16,096 
  16,948 
Mandatorily redeemable Series B convertible preferred stock
  3,200 
  3,149 
Accrued property taxes
  4,972 
  4,095 
Accrued contingent litigation fees
  6,200 
  6,200 
Current portion of operating lease liability
  223 
  377 
Other current liabilities
  5,371 
  5,290 
Total current liabilities
  59,998 
  57,819 
Long term liabilities:
    
    
Senior secured notes and revolving notes
  116,477 
  107,205 
EB-5 notes
  36,000 
  36,500 
GAFI secured and revolving notes
  31,290 
  29,856 
Other long term debt
  12,037 
  6,124 
Series A preferred units
  24,301 
  14,077 
Operating lease liability
  2,730 
  200 
Other long term liabilities
  3,524 
  2,487 
Total long term liabilities
  226,359 
  196,449 
 
    
    
Stockholders' deficit:
    
    
Series B convertible preferred stock, $0.001 par value; 7,235 authorized; 1,323 shares issued and outstanding each period, respectively (aggregate liquidation preference of $3,969 for each period respectively)
  1 
  1 
Common stock, $0.001 par value; 40,000 authorized; 20,683 and 20,570 shares issued and outstanding each period, respectively
  21 
  21 
Additional paid-in capital
  87,580 
  86,852 
Accumulated deficit
  (247,281)
  (237,421)
Accumulated other comprehensive loss
  (4,520)
  (3,825)
Total stockholders' deficit
  (164,199)
  (154,372)
Total liabilities and stockholders' deficit
 $122,158 
 $99,896 
 
The accompanying notes are an integral part of the financial statements.
 
 
4
 
 
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME (LOSS)
(Unaudited, in thousands except for earnings per share)
 
 
 
For the three months ended June 30,
 
 
For the six months ended June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Revenues
 $47,824 
 $50,619 
 $87,304 
 $92,507 
Cost of goods sold
  33,765 
  47,346 
  73,678 
  89,585 
Gross profit
  14,059 
  3,273 
  13,626 
  2,922 
 
    
    
    
    
Research and development expenses
  21 
  90 
  138 
  123 
Selling, general and administrative expenses
  4,049 
  3,945 
  7,985 
  8,186 
Operating income (loss)
  9,989 
  (762)
  5,503 
  (5,387)
 
    
    
    
    
Other (income) expense:
    
    
    
    
Interest expense
    
    
    
    
Interest rate expense
  5,574 
  5,190 
  11,160 
  10,176 
Debt related fees and amortization expense
  614 
  1,396 
  1,904 
  2,619 
Accretion of Series A preferred units
  1,362 
  471 
  2,322 
  920 
Loss contingency on litigation
  - 
  6,200 
  - 
  6,200 
Other (income) expense
  303 
  (89)
  240 
  (712)
 Income (loss) before income taxes
  2,136 
  (13,930)
  (10,123)
  (24,590)
Income tax expense (benefit)
  (56)
  - 
  (263)
  7 
Net income (loss)
 $2,192 
 $(13,930)
 $(9,860)
 $(24,597)
 
    
    
    
    
Less: Net loss attributable to non-controlling interest
  - 
  (994)
  - 
  (1,932)
Net income (loss) attributable to Aemetis, Inc.
 $2,192 
 $(12,936)
 $(9,860)
 $(22,665)
 
    
    
    
    
Other comprehensive income (loss)
    
    
    
    
Foreign currency translation gain (loss)
  (27)
  57 
  (695)
  115 
Comprehensive income (loss)
 $2,165 
 $(13,873)
 $(10,555)
 $(24,482)
 
    
    
    
    
Net income (loss) per common share
    
    
    
    
Basic
 $0.11 
 $(0.63)
 $(0.48)
 $(1.11)
Diluted
 $0.10 
 $(0.63)
 $(0.48)
 $(1.11)
 
    
    
    
    
Weighted average shares outstanding
    
    
    
    
Basic
  20,683 
  20,375 
  20,668 
  20,371 
Diluted
  21,152 
  20,375 
  20,668 
  20,371 
 
The accompanying notes are an integral part of the financial statements.
 
 
5
 
 
AEMETIS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
 (Unaudited, in thousands)
 
 
 
For the six months ended June 30,
 
 
 
2020
 
 
2019
 
Operating activities:
 
 
 
 
 
 
Net loss
 $(9,860)
 $(24,597)
 
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
 
    
Share-based compensation
  635 
  486 
Depreciation
  2,262 
  2,234 
Debt related fees and amortization expense
  1,904 
  2,619 
Intangibles and other amortization expense
  24 
  24 
Accretion of Series A preferred units
  2,322 
  920 
Deferred tax benefit
  (263)
  - 
Change in fair value of stock appreciation rights
  - 
  60 
Changes in operating assets and liabilities:
    
    
Accounts receivable
  (3,233)
  (2,708)
Inventories
  (1,016)
  2,042 
Prepaid expenses
  (339)
  351 
Other assets
  1,570 
  561 
Accounts payable
  721 
  2,704 
Accrued interest expense and fees
  10,433 
  8,301 
Other liabilities
  (302)
  5,772 
Net cash provided by (used in) operating activities
  4,858 
  (1,231)
 
    
    
Investing activities:
    
    
Capital expenditures
  (8,621)
  (1,038)
Net cash used in investing activities
  (8,621)
  (1,038)
 
    
    
Financing activities:
    
    
Proceeds from borrowings
  6,861 
  15,740 
Repayments of borrowings
  (7,524)
  (14,065)
GAFI renewal fee payment
  - 
  (500)
Payments on finance leases
  (702)
  - 
Proceeds from Series A preferred units financing
  7,902 
  250 
Net cash provided by financing activities
  6,537 
  1,425 
 
    
    
Effect of exchange rate changes on cash and cash equivalents
  (20)
  6 
Net change in cash and cash equivalents for period
  2,754 
  (838)
Cash and cash equivalents at beginning of period
  656 
  1,188 
Cash and cash equivalents at end of period
 $3,410 
 $350 
 
    
    
Supplemental disclosures of cash flow information, cash paid:
    
    
Cash paid for interest, net of capitalized interest of $183 and $147
 $539 
 $1,699 
Income taxes paid
  8 
  - 
Supplemental disclosures of cash flow information, non-cash transactions:
    
    
Subordinated debt extension fees added to debt
  340 
  340 
Fair value of warrants issued to subordinated debt holders
  93 
  67 
TEC debt extension, waiver fees, promissory notes fees added to debt
  1,076 
  1,102 
Capital expenditures in accounts payable
  2,132 
  1,882 
Operating lease liabilities arising from obtaining right of use assets
  2,632 
  1,181 
Financing lease liabilities arising from obatining right of use assets
  2,881 
  - 
Capital expenditures purchased on financing
  5,652 
  - 
 
The accompanying notes are an integral part of the financial statements.
 
 
6
 
 
AEMETIS, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT
(Unaudited, in thousands)
 
 
For the three and six months ended June 30, 2020
 
Description
 
Series B Preferred Stock
 
 
Common Stock
 
 
 
 
 
 
 
 
Accumulated Other
 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional
 
 
Accumulated
 
 
Comprehensive
 
 
 Stockholders'
 
 
 
Shares
 
 
Dollars
 
 
Shares
 
 
Dollars
 
 
Paid-in Capital
 
 
Deficit
 
 
Income/(Loss)
 
 
 deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2019
  1,323 
 $1 
  20,570 
 $21 
 $86,852 
 $(237,421)
 $(3,825)
 $(154,372)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  - 
  - 
  310 
  - 
  - 
  310 
Issuance and exercise of warrants
  - 
  - 
  113 
  - 
  93 
  - 
  - 
  93 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (668)
  (668)
Net loss
  - 
  - 
  - 
  - 
  - 
  (12,052)
  - 
  (12,052)
 
    
    
    
    
    
    
    
    
Balance at March 31, 2020
  1,323 
 $1 
  20,683 
 $21 
 $87,255 
 $(249,473)
 $(4,493)
 $(166,689)
 
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  - 
  - 
  325 
  - 
  - 
  325 
Foreign currency translation loss
  - 
  - 
  - 
  - 
  - 
  - 
  (27)
  (27)
Net income
  - 
  - 
  - 
  - 
  - 
  2,192 
  - 
  2,192 
 
    
    
    
    
    
    
    
    
Balance at June 30, 2020
  1,323 
 $1 
  20,683 
 $21 
 $87,580 
 $(247,281)
 $(4,520)
 $(164,199)
 
 
 For the three and six months ended June 30, 2019
Description
 
Series B Preferred Stock
 
 
Common Stock
 
 
 
 
 
 
 
 
Accumulated Other
 
 

 
 
Total
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Additional
 
 
Accumulated
 
 
Comprehensive
 
 
 Noncontrolling
 
 
 Stockholders'
 
 
 
Shares
 
 
Dollars
 
 
Shares
 
 
Dollars
 
 
Paid-in Capital
 
 
Deficit
 
 
Income/(Loss)
 
 
 Interest
 
 
 deficit
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance at December 31, 2018
  1,323 
 $1 
  20,345 
 $20 
 $85,917 
 $(193,204)
 $(3,576)
 $(4,740)
 $(115,582)
 
    
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  - 
  - 
  290 
  - 
  - 
  - 
  290 
Issuance and exercise of warrants
  - 
  - 
  30 
  - 
  67 
  - 
  - 
  - 
  67 
Foreign currency translation gain
  - 
  - 
  - 
  - 
  - 
  - 
  58 
  - 
  58 
Net loss
  - 
  - 
  - 
  - 
  - 
  (9,729)
  - 
  (938)
  (10,667)
 
    
    
    
    
    
    
    
    
    
Balance at March 31, 2019
  1,323 
 $1 
  20,375 
 $20 
 $86,274 
 $(202,933)
 $(3,518)
 $(5,678)
 $(125,834)
 
    
    
    
    
    
    
    
    
    
Stock-based compensation
  - 
  - 
  - 
  - 
  196 
  - 
  - 
  - 
  196 
Foreign currency translation gain
  - 
  - 
  - 
  - 
  - 
  - 
  57 
  - 
  57 
Net loss
  - 
  - 
  - 
  - 
  - 
  (12,936)
  - 
  (994)
  (13,930)
 
    
    
    
    
    
    
    
    
    
Balance at June 30, 2019
  1,323 
 $1 
  20,375 
 $20 
 $86,470 
 $(215,869)
 $(3,461)
 $(6,672)
 $(139,511)
 
 
7
 
 
AEMETIS, INC.
 
NOTES TO CONSOLIDATED CONDENSED FINANCIAL STATEMENTS
(Unaudited, tabular data in thousands except par value and per share data)
 
1.          
Nature of Activities and Summary of Significant Accounting Policies
 
Nature of Activities. Headquartered in Cupertino, California, Aemetis, Inc. (collectively with its subsidiaries on a consolidated basis, “Aemetis,” the “Company,” “we,” “our” or “us”) is an advanced renewable fuels and biochemicals company focused on the acquisition, development and commercialization of innovative technologies that replace traditional petroleum-based products through the conversion of second-generation ethanol and biodiesel plants into advanced biorefineries.  Founded in 2006, we own and operate a 65 million gallon per year renewable ethanol facility (“Keyes Plant”) in California’s Central Valley, near Modesto, where we manufacture and produce ethanol, high grade alcohol, wet distillers’ grains (“WDG”), condensed distillers solubles (“CDS”), and distillers’ corn oil (“DCO”). We also own and operate a 50 million gallon per year renewable chemical and advanced fuel production facility (“Kakinada Plant”) on the East Coast of India that produces high quality distilled biodiesel and refined glycerin for customers in India and Europe. We operate a research and development laboratory to develop efficient conversion technologies using waste feedstocks to produce biofuels and biochemicals. Additionally, we own a partially completed plant in Goodland, Kansas (the “Goodland Plant”) through our subsidiary Goodland Advanced Fuels, Inc., (“GAFI”), which was formed to acquire the Goodland Plant. On December 31, 2019 we exercised an option to acquire all capital stock of GAFI for $10 and consolidated assets, liabilities, and equity of GAFI as a wholly-owned subsidiary from December 31, 2019. Prior to December 31, 2019, GAFI activity is shown as non-controlling interest in the consolidated statements of operations.
 
We also lease a site in Riverbank, California, near the Keyes Plant, where we plan to utilize biomass-to-fuel technology that we have licensed from LanzaTech Technology (“LanzaTech”) and InEnTec Technology (“InEnTec”) to build a cellulosic ethanol production facility (the “Riverbank Cellulosic Ethanol Facility”) capable of converting local California surplus biomass – principally agricultural orchard waste – into ultra-low carbon renewable cellulosic ethanol (the “Riverbank Project”). By producing ultra-low carbon renewable cellulosic ethanol, we expect to capture higher value D3 cellulosic renewable identification numbers (“RINs”) and California Low Carbon Fuel Standard (“LCFS”) credits.
 
In December 2018, we acquired a 5.2-acre parcel of land for the construction of a gas-to-liquid CO2 production facility by Messer. Aemetis sells carbon dioxide (“CO2”) produced at the Keyes Plant (the “CO2 Project”) to Messer for conversion and sale into the food processing, beverage, and technology sectors. The Aemetis portion of the CO2 Project construction was completed in January 2020, and Messer completed construction on their portion in April 2020. We commenced operations in late April 2020, and started recognizing revenue from this project in the second quarter of 2020.
 
In 2018, we formed Aemetis Biogas, LLC (“ABGL”) to construct a cluster of anaerobic biogas digesters at local dairies near the Keyes Plant (the “Biogas Project”) to produce ultra-low carbon renewable natural gas (“RNG”) for use as transportation fuel. Construction of the first two dairy digesters and pipeline in the cluster will be completed in August 2020. ABGL has signed participation agreements or fully executed leases with nearly 20 local dairies near the Keyes Plant to build anerobic digesters to capture methane gas from manure lagoons at such dairies, which would otherwise be released into the atmosphere. We plan to capture methane-rich biogas from multiple dairies and convey the gas via a private underground pipeline to a centralized location at our Keyes Plant, where we will remove impurities in the gas and convert it into RNG for injection into the local utility pipeline operated by PG&E or to a renewable compressed natural gas (“RCNG”) truck loading station that will service local trucking fleets to displace diesel fuel. The biogas can also be used as energy in our Keyes Plant to displace petroleum-based natural gas. We believe the environmental and economic benefits of the Biogas Project are potentially significant due to dairy biogas having a negative carbon intensity (“CI”) under the California LCFS. The biogas produced by ABGL is expected to also receive D3 RINs under the federal Renewable Fuel Standard (“RFS”).
 
 
8
 
 
On March 18, 2020, in order to address a supply shortage of hand sanitizer during the worldwide COVID-19 pandemic, the US Treasury Tobacco and Alcohol Tax and Trade Bureau (“TTB”) provided emergency waivers allowing fuel ethanol plants to produce high grade alcohol for use in the production of hand sanitizer. Concurrently, during the first week of April 2020, Aemetis applied for and was approved by the TTB as a Distilled Spirits Producer (“DSP”), which would allow the company to produce, in addition to fuel ethanol, high-grade alcohol for sanitizer and other health care and sanitary products, as well as industrial alcohol and potable alcohol for beverage spirits once the temporary waiver period expires. Accordingly, Aemetis began supplying high-grade alcohol for the production of hand sanitizer. Aemetis has also implemented a series of capital projects at the Keyes facility that will ultimately enable the production of US Pharmacopeia (“USP”) grade alcohol for sale into these key consumer and industrial markets. During June 2020, Aemetis renamed Biofuels Marketing, Inc. as Aemetis Health Products, Inc., and began a sales and marketing strategy of blending, bottling and selling hand sanitizer into bulk, retail branded, and white label markets.
 
Basis of Presentation and Consolidation. These consolidated financial statements include the accounts of Aemetis. Additionally, we consolidate all entities in which we have a controlling financial interest either directly or by option to acquire the interest. A controlling financial interest is usually obtained through ownership of a majority of the voting interests. However, an enterprise must consolidate a variable interest entity (“VIE”) if the enterprise is the primary beneficiary of the VIE, even if the enterprise does not own a majority of the voting interests. The primary beneficiary is the party that has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance, and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. Prior to December 31, 2019, GAFI was consolidated into the financial statements as a VIE. On December 31, 2019, we exercised an option to acquire all capital stock of GAFI for $10 and consolidated assets, liabilities, and equity of GAFI into the accounts of Aemetis from December 31, 2019 forward.
 
The accompanying consolidated condensed balance sheet as of June 30, 2020, the consolidated condensed statements of operations and comprehensive income (loss) for the three and six months ended June 30, 2020 and 2019, the consolidated condensed statements of cash flows for the six months ended June 30, 2020 and 2019, and the consolidated condensed statements of stockholders’ deficit for the three and six months ended June 30, 2020 and 2019 are unaudited. The consolidated condensed balance sheet as of December 31, 2019 was derived from the 2019 audited consolidated financial statements and notes thereto. The consolidated condensed financial statements in this report should be read in conjunction with the 2019 audited consolidated financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2019. The accompanying consolidated condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations.
 
In the opinion of Company’s management, the unaudited interim consolidated condensed financial statements for the three and six months ended June 30, 2020 and 2019 have been prepared on the same basis as the audited consolidated statements as of December 31, 2019 and reflect all adjustments, consisting primarily of normal recurring adjustments, necessary for the fair presentation of its statement of financial position, results of operations and cash flows. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the operating results for any subsequent quarter, for the full fiscal year or any future periods.
 
Use of Estimates. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, revenues, and expenses during the reporting period. To the extent there are material differences between these estimates and actual results, the Company’s consolidated financial statements will be affected.
 
 
9
 
 
Revenue Recognition. We derive revenue primarily from sales of ethanol, high grade alcohol and related co-products in North America, and biodiesel and refined glycerin in India pursuant to supply agreements and purchase order contracts. We assessed the following criteria under the ASC 606 guidance: (i) identify the contracts with customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when the entity satisfies the performance obligations.
 
North America:  In North America, until May 13, 2020, we sold all our ethanol to J.D. Heiskell & Co. (“J.D. Heiskell”) under the Working Capital and Purchasing Agreement (the “J.D. Heiskell Purchasing Agreement”). On May 13, 2020, we entered into an amendment to the Corn Procurement and Working Capital Agreement with J.D. Heiskell (the “Corn Procurement and Working Capital”), under the terms of which we will buy all corn from J.D.Heiskell and sell all WDG and corn oil we produce to J.D.Heiskell. Following May 13, 2020, we sold the majority of our fuel ethanol production to one customer, Kinergy Marketing, LLC (“Kinergy”), under a supply contract, with individual sales transactions occurring under such contract. Given the similarity of these transactions, we have assessed them as a portfolio of similar contracts. The performance obligation is satisfied by delivery of the physical product to one of Kinergy’s contracted trucking companies. At this point in time, the customer has the ability to direct the use of the product and receive substantially all of its benefits. The transaction price is determined based on daily market prices negotiated by Kinergy for ethanol and by A.L. Gilbert Company (“A.L. Gilbert”) for WDG. There is no transaction price allocation needed.
 
During the first quarter of 2020, Aemetis began selling high grade alcohol for consumer applications directly to customers on the West Coast and Midwest using a variety of payment terms. These agreements and terms were evaluated according to ASC 606 guidance and such revenue is recognized upon satisfaction of the performance obligation by delivery of the product based on the terms of the agreement. Sales of high grade alcohol represented 48% and 28% of revenue for three and six months ended June 30, 2020, respectively.
 
 The below table shows our sales in North America by product category:
 
North America (in thousands)
 
 
 
 
 
 
 
 
 
 
 
 For the three months ended
June 30,
 
 
 For the six months ended
June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Ethanol sales
 $36,240 
 $29,808 
 $61,562 
 $56,997 
Wet distiller's grains sales
  7,466 
  8,733 
  15,840 
  17,336 
Other sales
  1,517 
  945 
  3,693 
  1,789 
 
 $45,223 
 $39,486 
 $81,095 
 $76,122 
 
 
10
 
 
We have elected to adopt the practical expedient that allows for ignoring the significant financing component of a contract when estimating the transaction price when the transfer of promised goods to the customer and customer payment for such goods are expected to be within one year of contract inception. Further, we have elected to adopt the practical expedient in which incremental costs of obtaining a contract are expensed when the amortization period would otherwise be less than one year.
 
We also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those customers in certain contractual agreements.
 
In North America, we assessed principal versus agent criteria as we buy corn as feedstock in producing ethanol from our working capital partner J.D. Heiskell and sell all WDG and corn oil produced in this process to J.D. Heiskell through A.L. Gilbert. We sold all ethanol we produced to J.D.Heiskell until May 13, 2020. We consider the purchase of corn as a cost of goods sold and the sale of ethanol upon transfer to the common carrier as revenue on the basis that (i) we control and bear the risk of gain or loss on the processing of corn which is purchased at market prices into ethanol and (ii) we have legal title to the goods during the processing time. The pricing for both corn and ethanol is set independently. Revenues from sales of ethanol and its co-products are billed net of the related transportation and marketing charges. Transportation charges are accounted for in cost of goods sold and marketing charges are accounted for in sales, general and administrative expense. Transportation and marketing charges are known within days of the transaction and are recorded at the actual amounts. The Company has elected to adopt an accounting policy under which these charges have been treated as fulfillment activities provided after control has transferred. As a result, these charges are recognized in cost of goods sold and selling, general and administrative expenses, respectively, when revenue is recognized. Revenues are recorded at the gross invoiced amount. Hence, we are the principal in North America sales scenarios where our customer and vendor may be the same.
 
India:  In India, we sell products pursuant to purchase orders (written or verbal) or by contract with governmental or international parties, in which performance is satisfied by delivery and acceptance of the physical product. Given that the contracts are sufficiently similar in nature, we have assessed these contracts as a portfolio of similar contracts as allowed under the practical expedient. Doing so does not result in a materially different outcome compared to individually accounting for each contract. All domestic and international deliveries are subject to certain specifications as identified in contracts. The transaction price is determined daily based on reference market prices for biodiesel, refined glycerin, and Palm Fatty Acid Distillers (“PFAD”) net of taxes. There is no transaction price allocation needed.
 
The below table shows our sales in India by product category:
 
India (in thousands)
 
 
 
 
 
 
 
 
 
 
 
 For the three months ended
June 30,
 
 
 For the six months ended
June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Biodiesel sales
 $2,149 
 $10,797 
 $4,942 
 $15,144 
Refined glycerin sales
  370 
  336 
  460 
  1,235 
PFAD sales
  62 
  - 
  774 
  - 
Other sales
  20 
  - 
  33 
  6 
 
 $2,601 
 $11,133 
 $6,209 
 $16,385 
 
 
11
 
 
In India, we also assessed principal versus agent criteria as we buy our feedstock from our customers and process and sell finished goods to those same customers in certain contractual agreements. In those cases, we receive the legal title to feedstock from our customers once it is on our premises. We control the processing and production of biodiesel based on contract terms and specifications. The pricing for both feedstock and biodiesel is set independently. We hold the title and risk to biodiesel according to agreements we enter into in these situations. Hence, we are the principal in India sales scenarios where our customer and vendor may be the same.
 
Cost of Goods Sold. Cost of goods sold includes those costs directly associated with the production of revenues, such as raw material consumed, factory overhead and other direct production costs. During periods of idle plant capacity, costs otherwise charged to cost of goods sold are reclassified to selling, general and administrative expense.
 
Accounts Receivable. The Company sells ethanol and WDG through third-party marketing arrangements generally without requiring collateral and high grade alcohol directly to customers on a variety of terms including advanced payment terms, based on the size and creditworthiness of the customer. DCO is marketed and sold to A.L. Gilbert and other customers under the J.D. Heiskell Purchasing Agreement. The Company sells CDS directly to customers on standard 30 day payment terms. The Company sells biodiesel, glycerin, and processed natural oils to a variety of customers and may require advanced payment based on the size and creditworthiness of the customer. Usually, invoices are due within 30 days on net terms. Accounts receivables consist of product sales made to large creditworthy customers. Trade accounts receivable are presented at original invoice amount, net of any allowance for doubtful accounts.
 
The Company maintains an allowance for doubtful accounts for balances that appear to have specific collection issues. The collection process is based on the age of the invoice and requires attempted contacts with the customer at specified intervals. If, after a specified number of days, the Company has been unsuccessful in its collection efforts, a bad debt allowance is recorded for the balance in question. Delinquent accounts receivables are charged against the allowance for doubtful accounts once un-collectability has been determined. The factors considered in reaching this determination are the apparent financial condition of the customer and the Company’s success in contacting and negotiating with the customer. If the financial condition of the Company’s customers were to deteriorate, additional allowances may be required. We did not reserve any balance for allowances for doubtful accounts as of June 30, 2020 and December 31, 2019.
 
Inventories. Finished goods, raw materials, and work-in-process inventories are valued using methods which approximate the lower of cost (first-in, first-out) or net realizable value (“NRV”). Distillers’ grains and related products are stated at NRV. In the valuation of inventories, NRV is determined as estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation.
 
Property, Plant and Equipment. Property, plant and equipment are carried at cost less accumulated depreciation after assets are placed in service and are comprised primarily of buildings, furniture, machinery, equipment, land, and the Keyes Plant, Goodland Plant and Kakinada Plant. The Goodland Plant is partially completed and is not ready for operation and the Riverbank Project and Biogas Project are being constructed and are not operating, hence we are not depreciating these assets yet. The CO2 Project was completed and commenced operations in the second quarter of 2020. Accordingly, any assets under the CO2 Project were capitalized in May 2020 and were depreciated starting May 2020. Otherwise, it is the Company’s policy to depreciate capital assets over their estimated useful lives using the straight-line method.
 
 
12
 
 
The Company evaluates the recoverability of long-lived assets with finite lives in accordance with ASC Subtopic 360-10-35 Property Plant and Equipment—Subsequent Measurements, which requires recognition of impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, based on estimated undiscounted cash flows, the impairment loss would be measured as the difference between the carrying amount of the assets and its estimated fair value. Additionally, the impact of the COVID-19 pandemic was assessed, and based upon this assessment, there is no impairment of assets needed.
 
California Energy Commission Technology Demonstration Grant. The Company has been awarded and completed the demonstration project associated with the $825 thousand matching grant program from the California Energy Commission (“CEC”) Natural Resources Agency to optimize the effectiveness of technologies to break down biomass to produce cellulosic ethanol. The Company has received all of the awarded grant proceeds as of June 30, 2020.  The project focused on the deconstruction and conversion of sugars liberated from California-relevant feedstocks and then converting the sugars to ethanol. The Company receives these funds as reimbursement for actual expenses incurred. Due to the uncertainty associated with the expense approval process under the grant program, the Company recognizes the grant as a reduction of the expenses in the period when approval is received.
 
California Department of Food and Agriculture Dairy Digester Research and Development Grant. The Company has been awarded $3.2 million in matching grants from the California Department of Food and Agriculture (“CDFA”) Dairy Digester Research and Development program. The CDFA grant reimburses the Company for costs required to permit and construct two of the Company’s biogas capture systems under contract with central California dairies. The Company received $2.6 million as of June 30, 2020 as reimbursement for actual costs incurred. Due to the uncertainty associated with the approval process under the grant program, the Company recognizes the grant as a reduction of the costs in the period when approval is received.
 
California Energy Commission Low Carbon Advanced Ethanol Grant Program. In May 2019, the Company was awarded the right to receive reimbursements from the CEC in an amount up to $5.0 million (the “CEC Reimbursement Program”) in connection with the Company’s expenditures toward the development of the Riverbank Cellulosic Ethanol Facility. To comply with the guidelines of the CEC Reimbursement Program, the Company must make a minimum of $7.9 million in matching contributions to the Riverbank Project. The Company receives the CEC funds under the CEC Reimbursement Program for actual expenses incurred up to $5.0 million as long as the Company makes the minimum matching contribution. Given that the Company has not made the minimum matching contribution, the grant of $1.36 million received for capital expenditures during the third quarter of 2019 was recorded as other long term liabilities as of June 30, 2020 and December 31, 2019.
 
Basic and Diluted Net Income (Loss) per Share. Basic net income (loss) per share is computed by dividing net income (loss) attributable to common shareholders by the weighted average number of common shares outstanding for the period. Diluted net income (loss) per share reflects the dilution of common stock equivalents such as options, convertible preferred stock, debt, and warrants to the extent the impact is dilutive. As the Company incurred net income for the three months ended June 30, 2020, potentially dilutive securities have been included in the diluted net income per share computations and any potentially anti-dilutive shares have been excluded and are shown below. As the Company incurred net losses for the six months ended June 30, 2020 and 2019 and three months ended June 30, 2019, potentially dilutive securities have been excluded from the diluted net loss per share computations as their effect would be anti-dilutive.
 
 
13
 
 
The following table reconciles the number of shares utilized in the net income (loss) per share calculations for three and six months ended June 30, 2020 and 2019:
 
 
 
Three months ended
 
 
Six months ended
 
 
 
June 30,
2020
 
 
June 30,
2019
 
 
June 30,
2020
 
 
June 30,
2019
 
 
 
(In thousands, except per share amounts)
 
 
(In thousands, except per share amounts)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income (loss)
 $2,192 
 $(12,936)
 $(9,860)
 $(22,665)
 
    
    
    
    
Shares:                                  
    
    
    
    
    Weighted average shares outstanding—basic
  20,683 
  20,375 
  20,668 
  20,371 
 
    
    
    
    
    Weighted average dilutive share equivalents from preferred shares
  132 
  - 
  - 
  - 
    Weighted average dilutive share equivalents from stock options
  337 
  - 
  - 
  - 
    Weighted average dilutive share equivalents from common warrants
  - 
  - 
  - 
  - 
 
    
    
    
    
Weighted average shares outstanding—diluted
  21,152 
  20,375 
  20,668 
  20,371 
 
    
    
    
    
 
    
    
    
    
        Income (loss) per share—basic
 $0.11 
 $(0.63)
 $(0.48)
 $(1.11)
 
    
    
    
    
       Income (loss) per share—diluted
 $0.10 
 $(0.63)
 $(0.48)
 $(1.11)
 
The following table shows the number of potentially dilutive shares excluded from the diluted net loss per share calculation as of June 30, 2020 and 2019:
 
 
 
As of
 
 
 
June 30,
2020
 
 
June 30,
2019
 
 
 
 
 
 
 
 
Series B preferred
  - 
  132 
Common stock options and warrants
  2,950 
  3,994 
Debt with conversion feature at $30 per share of common stock
  1,271 
  1,247 
SARs conversion if stock issued at $1.02 per share to cover $2.1 million
  - 
  2,062 
Total number of potentially dilutive shares excluded from the diluted net income (loss) per share calculation
  4,221 
  7,435 
 
Comprehensive Loss. ASC 220 Comprehensive Income requires that an enterprise report, by major components and as a single total, the change in its net assets from non-owner sources. The Company’s other comprehensive income (loss) and accumulated other comprehensive loss consists solely of cumulative currency translation adjustments resulting from the translation of the financial statements of its foreign subsidiary.
 
 
14
 
 
Foreign Currency Translation/Transactions. Assets and liabilities of the Company’s non-U.S. subsidiary that operates in a local currency environment, where that local currency is the functional currency, are translated into U.S. dollars at exchange rates in effect at the balance sheet date and the resulting translation adjustments directly recorded to a separate component of accumulated other comprehensive loss. Income and expense accounts are translated at average exchange rates during the year. Transactional gains and losses from foreign currency transactions are recorded in other (income) loss, net.
 
Operating Segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. Aemetis recognized two reportable geographic segments: “North America” and “India.”
 
The “North America” operating segment includes the Keyes Plant, the Riverbank Cellulosic Ethanol Facility, the Biogas Project, the Goodland Plant and the research and development facility in Minnesota.
 
The “India” operating segment includes the Company’s 50 million gallon per year capacity Kakinada Plant in India, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius.
 
Fair Value of Financial Instruments. Financial instruments include accounts receivable, accounts payable, accrued liabilities, current and non-current portion of subordinated debt, notes payable, and long-term debt.  Due to the unique terms of our notes payable and long-term debt and the financial condition of the Company, the fair value of the debt is not readily determinable.  The fair value, determined using level 3 inputs, of all other current financial instruments is estimated to approximate carrying value due to the short-term nature of these instruments.
 
Share-Based Compensation. The Company recognizes share-based compensation expense in accordance with ASC 718 Stock Compensation requiring the Company to recognize expenses related to the estimated fair value of the Company’s share-based compensation awards at the time the awards are granted, adjusted to reflect only those shares that are expected to vest.
 
Commitments and Contingencies. The Company records and/or discloses commitments and contingencies in accordance with ASC 450 Contingencies. ASC 450 applies to an existing condition, situation or set of circumstances involving uncertainty as to possible loss that will ultimately be resolved when one or more future events occur or fail to occur.
 
Debt Modification Accounting. The Company evaluates amendments to its debt in accordance with ASC 470-50 Debt–Modification and Extinguishments for modification and extinguishment accounting. This evaluation includes comparing the net present value of cash flows of the new debt to the old debt to determine if changes greater than 10 percent occurred. In instances where the net present value of future cash flows changed more than 10 percent, the Company applies extinguishment accounting and determines the fair value of its debt based on factors available to the Company.
 
We have evaluated the 1% extension fee for extending the maturity date to April 1, 2021, in accordance with ASC 470-60 Troubled Debt Restructuring. For additional information regarding the 1% extension fee, please see “Part I, Item 1. Financial Statements – Note 4. Debt.”
 
 
15
 
 
Convertible Instruments. The Company evaluates the impacts of convertible instruments based on the underlying conversion features. Convertible instruments are evaluated for treatment as derivatives that could be bifurcated and recorded separately. Any beneficial conversion feature is recorded based on the intrinsic value difference at the commitment date.
 
Recently Issued Accounting Pronouncements.
 
For a complete summary of the Company’s significant accounting policies, please refer to the Company’s audited financial statements and notes thereto for the years ended December 31, 2019 and 2018 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 12, 2020. There were no new accounting pronouncements issued applicable to the Company during the three and six months ended June 30, 2020.
 
2.            
Inventories
 
Inventories consist of the following:
 
 
 
As of
 
 
 
June 30,
2020
 
 
December 31,
2019
 
Raw materials
 $1,981 
 $2,566 
Work-in-progress
  1,324 
  1,455 
Finished goods
  3,985 
  2,497 
Total inventories
 $7,290 
 $6,518 
 
As of June 30, 2020 and December 31, 2019, the Company recognized a lower of cost or net realizable value impairment of $0.1 million respectively, related to inventory.
 
3.          
Property, Plant and Equipment
 
Property, plant and equipment consist of the following:
  
 
As of
 
 
 
June 30,
2020
 
 
December 31,
2019
 
Land
 $4,076 
 $4,104 
Plant and buildings
  86,559 
  83,139 
Furniture and fixtures
  1,095 
  1,094 
Machinery and equipment
  4,190 
  4,252 
Construction in progress
  22,603 
  12,571 
Property held for development
  15,408 
  15,408 
Finance lease right of use assets
  2,881 
  - 
Total gross property, plant & equipment
  136,812 
  120,568 
Less accumulated depreciation
  (38,287)
  (36,342)
Total net property, plant & equipment
 $98,525 
 $84,226 
 
Construction in progress contains incurred costs for the Biogas Project, Riverbank Project, and Zebrex equipment installation at the Keyes Plant. In the second quarter of 2020, CO2 Project commenced operations and was placed in service at that time. Depreciation on the components of property, plant and equipment is calculated using the straight-line method to allocate their depreciable amounts over their estimated useful lives as follows:
 
 
16
 
 
 
 
Years
 
Plat and Buildings
20-30
 
Machinery & Equipment
5-7
 
Furniture & Fixtures
3-5
 
 
For the three months ended June 30, 2020 and 2019, the Company recorded depreciation expense of $1.2 million and $1.1 million for each period. For the six months ended June 30, 2020 and 2019, the Company recorded depreciation expense of $2.3 million and $2.2 million, respectively.
 
Management is required to evaluate these long-lived assets for impairment whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. Management determined there was no impairment on the long-lived assets during the three and six months ended June 30, 2020 and 2019.
 
4.          
Debt
 
Debt consists of the notes from our senior lender, Third Eye Capital, other working capital lenders and subordinated lenders as follows:
 
 
 
June 30,
2020
 
 
December 31,
2019
 
Third Eye Capital term notes
 $7,038 
 $7,024 
Third Eye Capital revolving credit facility
  71,308 
  62,869 
Third Eye Capital revenue participation term notes
  11,821 
  11,794 
Third Eye Capital acquisition term notes
  26,310 
  25,518 
Third Eye Capital promissory note
  2,231 
  2,815 
Cilion shareholder seller notes payable
  6,199 
  6,124 
Subordinated notes
  11,988 
  11,502 
Term loan on Equipment purchase
  5,652 
  - 
EB-5 promissory notes
  42,246 
  41,932 
PPP loans
  1,134 
  - 
Unsecured working capital loans
  1,370 
  2,631 
GAFI Term and Revolving loans
  32,172 
  30,216 
Total debt
  219,469 
  202,425 
Less current portion of debt
  23,665 
  22,740 
Total long term debt
 $195,804 
 $179,685 
 
On July 6, 2012, Aemetis, Inc. and Aemetis Advanced Fuels Keyes, Inc. (“AAFK”), entered into an Amended and Restated Note Purchase Agreement with Third Eye Capital (the “Note Purchase Agreement”). Pursuant to the Note Purchase Agreement, Third Eye Capital extended credit in the form of (i) senior secured term loans in an aggregate principal amount of approximately $7.2 million to replace existing notes held by Third Eye Capital (the “Term Notes”); (ii) senior secured revolving loans in an aggregate principal amount of $18.0 million (the “Revolving Credit Facility”); (iii) senior secured term loans in the principal amount of $10.0 million to convert the prior revenue participation agreement to a note (the “Revenue Participation Term Notes”); and (iv) senior secured term loans in an aggregate principal amount of $15.0 million (the “Acquisition Term Notes”) used to fund the cash portion of the acquisition of Cilion, Inc. (the Term Notes, Revolving Credit Facility, Revenue Participation Term Notes and Acquisition Term Notes are referred to herein collectively as the “Original Third Eye Capital Notes”).
 
 
17
 
 
On March 27, 2018, Third Eye Capital agreed to Limited Waiver and Amendment No. 14 to the Note Purchase Agreement (“Amendment No. 14”) to: (i) extend the maturity date of the Third Eye Capital Notes by two years to April 1, 2020 in exchange for an amendment fee consisting of 6% (3% per year) of the outstanding note balance in the form of an increase in the fee payable in the event of a redemption of the Third Eye Capital Notes (as defined in the Note Purchase Agreement); (ii) provide that the maturity date may be further extended at our election to April 1, 2021 in exchange for an extension fee of 5%; (iii) provide for an optional waiver of the ratio of note indebtedness covenant until January 1, 2019 with the payment of a waiver fee of $0.25 million; and (iv) remove the redemption fee described in (i) above from the calculation of the ratio of note indebtedness covenant. In addition to the fee discussed in (i), as consideration for such amendment and waiver, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.5 million to be added to the outstanding principal balance of the Revolving Credit Facility.
 
Based on the terms of Amendment No. 14, on April 1, 2020, the Company exercised option to extend the maturity to April 1, 2021 for a reduced fee of 1% on the outstanding debt which was added to the outstanding balance of the notes on April 1, 2020.
 
On March 11, 2019, Third Eye Capital agreed to Limited Waiver and Amendment No. 15 to the Note Purchase Agreement (“Amendment No. 15”), to waive the ratio of note indebtedness covenant through December 31, 2019. As a consideration for this amendment, the Company also agreed to pay Third Eye Capital an amendment fee of $1.0 million to be added to the redemption fee which is due upon redemption of the Notes.
 
On November 11, 2019, Third Eye Capital agreed to Limited Waiver and Amendment No. 16 to the Note Purchase Agreement (“Amendment No. 16”), to waive the ratio of note indebtedness covenant for the quarters ended March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020. As a consideration for this amendment, the Company also agreed to pay Third Eye Capital an amendment fee of $0.5 million to be added to the redemption fee which is due upon redemption of the Notes.
 
On August 11, 2020, Third Eye Capital agreed to Limited Waiver and Amendment No. 17 to the Note Purchase Agreement (“Amendment No. 17”) to: (i) provide that the maturity date may be further extended at our election to two 1-year terms to April 1, 2022 in exchange for an extension fee equal to 1% of the Note Indebtedness in respect to each Note, provided that such fee may be added to the outstanding principal balance of each Note on the effective date of each such extension, (ii) provide for a waiver of the ratio of note indebtedness covenant for the quarters ended March 31, 2021 and June 30, 2021. As consideration for such amendment and waivers, the borrowers also agreed to pay Third Eye Capital an amendment and waiver fee of $0.3 million in cash or $0.4 million worth of shares of the Company issued at the 10-day weighted average price. We will evaluate the Amendment No. 17 in accordance with ASC 470-50 Debt – Modification and Extinguishment.
 
Based on Amendment No. 16, the ratio of note indebtedness covenant is waived for the quarters ended September 30, 2020 and December 31, 2020. Based on the Amendment No. 17 above, the ratio of note indebtedness covenant is waived for the quarters ended March 31, 2021 and June 30, 2021. According to ASC 470-10-45 debt covenant classification guidance, if it is probable that the Company will not be able to cure the default at measurement dates within the next 12 months, the related debt needs to be classified as current. As the Amendment No. 16 and Amendment No. 17 waived the ratio of the note indebtedness covenant over the next four quarters, the notes are classified as long-term debt.
 
 
18
 
 
On February 27, 2019, a Promissory Note (the “February 2019 Note”, together with the Original Third Eye Capital Notes, the “Third Eye Capital Notes”) for $2.1 million was advanced by Third Eye Capital to Aemetis, Inc., as a short-term credit facility for working capital and other general corporate purposes with an interest rate of 14% per annum maturing on the earlier of (a) receipt of proceeds from any financing, refinancing, or other similar transaction, (b) extension of credit by payee, as lender or as agent on behalf of certain lenders, to the Company or its affiliates, or (c) April 30, 2019. In consideration of the February 2019 Note, $0.1 million of the total proceeds were paid to Third Eye Capital as financing charges. On April 30, 2019, the February 2019 Note was modified to remove the stated maturity date and instead will be due on demand by Third Eye Capital. In third quarter of 2019, the February 2019 Note was modified to include additional borrowings of $0.7 million. In first quarter of 2020, the February 2019 Note was modified to include additional borrowings of $0.6 million. As of June 30, 2020, the outstanding balance of principal and interest on the February 2019 Note was $2.2 million.
 
On April 1, 2020, the Company exercised the option to extend the maturity of Third Eye Capital Notes to April 1, 2021 for a fee of 1% of the outstanding note balance instead of agreed fee of 5% in the Amendment No.14. We have evaluated the reduction in extension fee to 1% in accordance with ASC 470-60 Troubled Debt Restructuring. According to the guidance, we considered 1% extension fee to be a troubled debt restructuring. We assessed all the terms to confirm if there is a concession granted by the creditor. The maturity date of the Third Eye Capital Notes was extended to April 1, 2021 for a 1% fee, which was lower than the extension fee of 5% provided by Amendment No. 14 for a one-year extension. In order to assess whether the creditor granted a concession, we calculated the post-restructuring effective interest rate by projecting cash flows on the new terms and calculated a discount rate equal to the carrying amount of pre-restructuring of debt, and by comparing this calculation to the terms of Amendment No. 15, we determined that Third Eye Capital provided a concession in accordance with the provisions of ASC 470-60 Troubled Debt Restructuring and thus applied troubled debt restructuring accounting, resulting in no gain or loss from the application of this accounting. Using the effective interest method of amortization, the 1% extension fee of $1.0 million will be amortized over the stated remaining life of the Third Eye Capital Notes.
 
Terms of Third Eye Capital Notes
 
A. 
Term Notes. As of June 30, 2020, the Company had $7.0 million in principal and interest outstanding under the Term Notes net of $55 thousand unamortized discount issuance costs. The Term Notes accrue interest at 14% per annum and mature on April 1, 2021*.
 
B 
Revolving Credit Facility. The Revolving Credit Facility accrues interest at the prime rate plus 13.75% (17.00% as of June 30, 2020), payable monthly in arrears. The Revolving Credit Facility matures on April 1, 2021*. As of June 30, 2020, AAFK had $71.3 million in principal and interest and waiver fees outstanding under the Revolving Credit Facility net of $0.5 million unamortized discount issuance costs.
 
C. 
Revenue Participation Term Notes. The Revenue Participation Term Note bears interest at 5% per annum and matures on April 1, 2021*. As of June 30, 2020, AAFK had $11.8 million in principal and interest outstanding on the Revenue Participation Term Notes net of $90 thousand unamortized discount issuance costs.
 
D. 
Acquisition Term Notes. The Acquisition Term Notes accrue interest at the prime rate plus 10.75% (14.00% per annum as of June 30, 2020) and mature on April 1, 2021*. As of June 30, 2020, Aemetis Facility Keyes, Inc. had $26.3 million in principal and interest and redemption fees outstanding net of unamortized discount issuances costs of $0.1 million. The outstanding principal balance includes a total of $7.5 million in redemption fees.
 
E. 
Reserve Liquidity Notes. The Reserve Liquidity Notes, with available borrowing capacity in the amount of $18.0 million, accrue interest at the rate of 30% per annum and are due and payable upon the earlier of: (i) the closing of new debt or equity financings, (ii) receipt from any sale, merger, debt or equity financing, or (iii) April 1, 2021. We have no borrowings outstanding under the Reserve Liquidity Notes as of June 30, 2020.
 
 
19
 
 
The Third Eye Capital Notes contain various covenants, including but not limited to, debt to plant value ratio, minimum production requirements, and restrictions on capital expenditures. The terms of the Third Eye Capital Notes allow the lender to accelerate the maturity in the occurrence of any event that could reasonably be expected to have a material adverse effect, such as any change in the business, operations, or financial condition. The terms of the notes allow interest to be capitalized.
 
The Third Eye Capital Notes are secured by first priority liens on all real and personal property of, and assignment of proceeds from all government grants and guarantees from Aemetis, Inc. The Third Eye Capital Notes all contain cross-collateral and cross-default provisions. McAfee Capital, LLC (“McAfee Capital”), owned by Eric McAfee, the Company’s Chairman and CEO, provided a guaranty of payment and performance secured by all of its Company shares. In addition, Eric McAfee provided a blanket lien on substantially all of his personal assets, and McAfee Capital provided a guarantee in the amount of $8.0 million.
 
*The note maturity date can be extended by the Company to April 2022. As a condition to any such extension, the Company would be required to pay a fee of 1% of the carrying value of the debt which can be paid in cash or added to the outstanding debt. As a result of this ability to extend the maturity at the Company’s will, the Third Eye Capital Notes are classified as non-current debt.
 
Cilion shareholder seller notes payable. In connection with the Company’s merger with Cilion, Inc., (“Cilion”) on July 6, 2012, the Company issued $5.0 million in notes payable to Cilion shareholders as merger compensation subordinated to the senior secured Third Eye Capital Notes. The liability bears interest at 3% per annum and is due and payable after the Third Eye Capital Notes have been paid in full. As of June 30, 2020, Aemetis Facility Keyes, Inc. had $6.2 million in principal and interest outstanding under the Cilion shareholder seller notes payable.
 
Subordinated Notes. On January 6 and January 9, 2012, AAFK entered into Note and Warrant Purchase Agreements with two accredited investors (the “Note and Warrant Purchase Agreements”) pursuant to which it issued $0.9 million and $2.5 million in original notes to the investors (the “Subordinated Notes”). The Subordinated Notes mature every six months. Upon maturity, the Subordinated Notes are generally extended with a fee of 10% added to the balance outstanding plus issuance of warrants exercisable at $0.01 with a two-year term. Interest accrues at 10% and is due at maturity. Neither AAFK nor Aemetis may make any principal payments under the Subordinated Notes until all loans made by Third Eye Capital to AAFK are paid in full.
 
On July 1, 2020, the Subordinated Notes were amended to extend the maturity date until the earlier of (i) December 31, 2020; (ii) completion of an equity financing by AAFK or Aemetis in an amount of not less than $25.0 million; or (iii) after the occurrence of an Event of Default (as defined in the Note and Warrant Purchase Agreements), including failure to pay interest or principal when due and breaches of note covenants. A 10% cash extension fee was paid by adding the fee to the balance of the new note and warrants to purchase 113 thousand shares of common stock were granted with a term of two years and an exercise price of $0.01 per share. We will evaluate the July 1, 2020 amendment and the refinancing terms of the Subordinated Notes in accordance with ASC 470-50 Debt – Modification and Extinguishment.
 
At June 30, 2020 and December 31, 2019, the Company had, in aggregate, $12.0 million and $11.5 million in principal and interest outstanding respectively, under the Subordinated Notes.
 
 
20
 
 
EB-5 promissory notes. EB-5 is a U.S. government program authorized by the Immigration and Nationality Act designed to foster employment-based visa preference for immigrant investors to encourage the flow of capital into the U.S. economy and to promote employment of U.S. workers. The Company entered into a Note Purchase Agreement dated March 4, 2011 (as further amended on January 19, 2012 and July 24, 2012) with Advanced BioEnergy, LP, a California limited partnership authorized as a Regional Center to receive EB-5 investments, for the issuance of up to 72 subordinated convertible promissory notes (the “EB-5 Notes”) bearing interest at 2-3%. Each note was issued in the principal amount of $0.5 million and due and payable four years from the date of each note, for a total aggregate principal amount of up to $36.0 million (the “EB-5 Phase I funding”). The original maturity date on the promissory notes can be extended automatically for a one or two-year period initially and is eligible for further one-year automatic extensions as long as there is no notice of non-extension from investors and the investors’ immigration process is in progress. On February 27, 2019, Advanced BioEnergy, LP, and the Company entered into an Amendment to the EB-5 Notes which restated the original maturity date on the promissory notes with automatic six-month extensions as long as the investors’ immigration processes are in progress. Except for six early investor EB-5 Notes, the Company was granted 12 months from the date of the completion of immigration process to redeem these EB-5 Notes. Accordingly, the notes have been recognized as long-term debt while the five early investor notes and one investor who obtained the Green Card approval have been classified as current debt. The EB-5 Notes are convertible after three years at a conversion price of $30 per share.
 
Advanced BioEnergy, LP arranges investments with foreign investors, who each make loans to the Keyes Plant in increments of $0.5 million. The Company has sold an aggregate principal amount of $36.0 million of EB-5 Notes under the EB-5 Phase I funding since 2012 to the date of this filing. As of June 30, 2020, $35.0 million has been released from the escrow amount to the Company, with $0.5 million remaining in escrow and $0.5 million to be funded to escrow. As of June 30, 2020, $35.0 million in principal and $3.1 million in accrued interest was outstanding on the EB-5 Notes sold under the EB-5 Phase I funding.
 
On October 16, 2016, the Company launched its EB-5 Phase II funding, with plans to issue $50.0 million in additional EB-5 Notes on substantially similar terms and conditions as those issued under the Company’s EB-5 Phase I funding, to refinance indebtedness and capital expenditures of Aemetis, Inc. and GAFI (the “EB-5 Phase II funding”). On November 21, 2019, the minimum investment was raised from $0.5 million per investor to $0.9 million per investor. The Company entered into a Note Purchase Agreement dated with Advanced BioEnergy II, LP, a California limited partnership authorized as a Regional Center to receive EB-5 Phase II funding investments, for the issuance of up to 100 EB-5 Notes bearing interest at 3%. On May 1, 2020 Supplement No. 3 amended the offering documents and lowered the total eligible new EB-5 Phase II funding investors to 60. Eight EB-5 investors have already funded at the $0.5 million per investor amount, so 52 new EB-5 Phase II funding investors are eligible at the new $0.9 million per investor amount under the current offering. Job creation studies show additional investors may be possible to increase the total offering amount in the future. Each new note will be issued in the principal amount of $0.9 million and due and payable five years from the date of each note, for a total aggregate principal amount of up to $50.8 million.
 
Advanced BioEnergy II, LP arranges investments with foreign investors, who each make loans to the Riverbank Cellulosic Ethanol Facility in increments of $0.9 million after November 21, 2019. The Company has sold an aggregate principal amount of $4.0 million of EB-5 Notes under the EB-5 Phase II funding since 2016 to the date of this filing. As of June 30, 2020, $4.0 million was released from escrow to the Company and $46.8 million remains to be funded to escrow. As of June 30, 2020, $4.1 million in principal and interest was outstanding on the EB-5 Notes under the EB-5 Phase II funding.
 
 
21
 
 
Working capital loans. On April 16, 2017, the Company entered into an operating agreement with Gemini Edibles and Fats India Private Limited (“Gemini”). Under this agreement, Gemini agreed to provide the Company with working capital, on an as needed basis, to fund the purchase of feedstock and other raw materials for the Kakinada Plant. Working capital cash advances bear interest at 12% and working capital can be induced through trading of feedstock or finished goods by Gemini which does not have any interest accrual. In return, the Company agreed to pay Gemini an amount equal to 30% of the plant’s monthly net operating profit and recognized these as operational support charges in the financials. In the event that the Company’s biodiesel facility operates at a loss, Gemini owes the Company 30% of the losses as operational support charges. Either party can terminate the agreement at any time without penalty. Additionally, Gemini received a first priority lien on the assets of the Kakinada Plant. During the six months ended June 30, 2020, we have accrued no interest on Gemini balance as the investment was for feedstock purchase and finished goods trade. During the six months ended June 30, 2020 and 2019, the Company made principal payments to Gemini of approximately $5.7 million and $13.7 million, respectively. As of June 30, 2020 and December 31, 2019, the Company had approximately $1.4 million and $2.0 million outstanding under this agreement, respectively.
 
In November 2008, the Company entered into an operating agreement with Secunderabad Oils Limited (“Secunderabad Oils”). On July 15, 2017, the agreement with Secunderabad Oils was amended to provide the working capital funds for British Petroleum business operations only in the form of inter-corporate deposit for an amount of approximately $2.3 million over a 95 days period at the rate of 14.75% per annum interest rate. The term of the agreement continues until either party terminates it. Secunderabad Oils has a second priority lien on the assets of the Company’s Kakinada Plant after this agreement. On April 15, 2018, the agreement was amended to purchase the raw material for business operations at 12% per annum interest rate. During the six months ended June 30, 2020 and 2019, the Company made principal and interest payments to Secunderabad Oils of approximately $0.6 million and $0.5 million, respectively. As of June 30, 2020 and December 31, 2019, the Company had none and $0.6 million outstanding under this agreement, respectively.
 
GAFI Term loan and Revolving loan. On July 10, 2017, GAFI entered into a Note Purchase Agreement (“GAFI Note Purchase Agreement”) with Third Eye Capital (“Noteholders”). Pursuant to the GAFI Note Purchase Agreement, the Noteholders agreed, subject to the terms and conditions of the GAFI Note Purchase Agreement and relying on each of the representations and warranties set forth therein, to make (i) a single term loan to GAFI in an aggregate amount of $15 million (“GAFI Term Loan”) and (ii) revolving advances not to exceed ten million dollars in the aggregate (“GAFI Revolving Loan”). The interest rate per annum applicable to the GAFI Term Loan is equal to ten percent (10%). The interest rate per annum applicable to the GAFI Revolving Loans is the greater of Prime Rate plus seven and three quarters percent (7.75%) and twelve percent (12.00%). The applicable interest rate as of June 30, 2020 was 12.00%. The maturity date of the GAFI Term Loan and GAFI Revolving Loan (“GAFI Loan Maturity Date”) was July 10, 2020, provided that the GAFI Loan Maturity Date may be extended at the option of Aemetis for up to one-year period upon prior written notice and upon satisfaction of certain conditions and the payment of a renewal fee for such extension. The Company exercised the option to extend the GAFI Loan Maturity Date for a fee of $0.5 million and the current GAFI Loan Maturity Date is July 10, 2021. An initial advance under the GAFI Revolving Loan was made for $2.2 million as a prepayment of interest on the GAFI Term Loan for the first eighteen months of interest payments. In addition, a fee of $1.0 million was paid in consideration to Noteholders.
 
On June 28, 2018, GAFI entered into Amendment No. 1 to the GAFI Term Loan with Third Eye Capital for an additional amount of $1.5 million with a fee of $75 thousand added to the loan from Third Eye Capital at a 10% interest rate. On December 20, 2018, $1.6 million from Amendment No. 1 was repaid. Pursuant to Amendment No. 1, Aemetis, Inc. entered into a Stock Appreciation Rights Agreement to issue 1,050,000 Stock Appreciation Rights (“SARs”) to Third Eye Capital on August 23, 2018, with an exercise date of one year from the issuance date with a call option for the Company at $2.00 per share during the first 11 months of the agreement either to pay $2.1 million in cash or issue common stock worth $2.1 million based on the 30-day weighted average price of the stock on the call date, and a put option for Third Eye Capital at $1.00 per share during the 11th month of the agreement where the Company can redeem the SARs for $1.1 million in cash. In the event that none of the above options is exercised, the SARs will be automatically exercised one year from the issuance date based upon the 30-day weighted average stock price and paid in cash and cash equivalents. On July 22, 2019, Third Eye Capital exercised the put option at $1.00 per share for $1.1 million. The exercise value of the SARs of $1.1 million was added to the GAFI Term Loan and the SARs fair value liability was released.
 
 
22
 
 
On December 3, 2018, GAFI entered into Amendment No. 2 to the GAFI Term Loan with Third Eye Capital for an additional amount of $3.5 million from Third Eye Capital at a 10% interest rate. GAFI borrowed $1.8 million against this Amendment No. 2 with a $175 thousand fee added to the loan and $0.2 million was withheld from the $1.8 million for interest payments. $1.5 million is available to draw under GAFI Amendment No. 2 for the CO2 Project (“CO2 Term Loan”). Among other requirements, the Company is also required to make the following mandatory repayments of the CO2 Term Loan: (i) on a monthly basis, an amount equal to 75% of any payments received by the Company for CO2 produced by Linde LLC, (ii) an amount equal to 100% of each monthly payment received by the Company for land use by Linde for CO2 plant, (iii) on a monthly basis, an amount equal to the product of: $0.01 multiplied by the number of bushels of corn grain used in the ethanol production at the Keyes Plant. Based on the mandatory payments, an amount of $0.9 million is estimated to be paid in the next 12 months and is classified as current debt as of June 30, 2020.
 
As of June 30, 2020, GAFI had $21.0 million outstanding on the GAFI Term Loan and $11.1 million on the GAFI Revolving Loan respectively.
 
Payroll Protection Program. On May 5, 2020, certain wholly owned subsidiaries of the Company received loan proceeds of approximately $1.1 million, (“PPP Loans”) under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act (“CARES Act”), provides loans to qualifying businesses for payroll expenses of the qualifying business. The PPP Loan and accrued interest are forgivable after twenty-four weeks if the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the twenty-four-week period. The Company anticipates that it will utilize the proceeds in accordance with the PPP guidelines and repay amounts that are not forgiven or utilized. In order to obtain full or partial forgiveness of the PPP Loan, the Company must request forgiveness and must provide satisfactory documentation in accordance with applicable Small Business Administration (“SBA”) guidelines.
 
The PPP Loans are evidenced by promissory notes, dated May 1, 2020 and April 30, 2020 (the “Notes”), between the Company, as Borrower, and Bank of America, N.A., as Lender (the “Lender”). The interest rate on the Note is 1.00% per annum. No payments of principal or interest are due during the six-month period beginning on the funding date (the “Deferral Period”). If the SBA does not confirm forgiveness or only partly confirms forgiveness of the PPP Loans, or Borrower fails to apply for loan forgiveness, the Borrower will be obligated to repay to the Bank the total outstanding balance remaining due under the PPP Loans, including principal and interest and in such case, the Lender will establish the terms for repayment of the Loan in a separate letter to be provided to the Borrower in which the letter will set forth the loan balance, the amount of each monthly payment, the interest rate (not in excess of a fixed rate of one percent (1.00%) per annum), the term of the PPP Loans, and the maturity date, which, if not established by the Lender, shall be two (2) years from the funding date of the PPP Loans.
 
 
23
 
 
Scheduled debt repayments for the Company’s loan obligations follow:
 
Twelve months ended June 30,
 
Debt Repayments
 
2021
 $23,665 
2022
  171,214 
2023
  14,935 
2024
  6,634 
2025
  2,436 
Thereafter
  1,403 
Total debt
  220,287 
Debt issuance costs
  (818)
Total debt, net of debt issuance costs
 $219,469 
 
5. Commitments and Contingencies
  
Leases
 
We have identified assets as the corporate office, warehouse, monitoring equipment and laboratory facilities over which we have control and obtain economic benefits fully. We classified these identified assets as operating leases after assessing the terms under classification guidance. We have entered into several leases for trailers and carbon units with purchase option at the end of the term. We have concluded that it is reasonably certain that we would exercise the purchase option at the end of the term, hence the leases were classified as finance leases. All of our leases have remaining term of less than a year to 8 years.
 
When discount rates implicit in leases cannot be readily determined, the Company uses the applicable incremental borrowing rate at lease commencement to perform lease classification tests on lease components and measure lease liabilities and ROU assets. The incremental borrowing rate used by the Company was based on weighted average baseline rates commensurate with the Company’s secured borrowing rate over a similar term. At each reporting period when there is a new lease initiated, the rates established for that quarter will be used.
 
The components of lease expense and sublease income was as follows:
 
 
 
Three months ended June 30,
 
 
Six months ended June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Operating lease cost
 
 
 
 
 
 
 
 
 
 
 
 
Operating lease expense
 $183 
 $143 
 $360 
 $324 
Short term lease expense
  15 
  12 
  29 
  53 
Variable lease expense
  26 
  17 
  60 
  49 
Sub lease income
  - 
  (51)
  - 
  (68)
Total operating lease cost
 $224 
 $121 
 $449 
 $358 
 
    
    
    
    
Finance lease cost
    
    
    
    
Amortization of right-of-use assets
 $61 
 $- 
 $61 
 $- 
   Interest on lease liabilities
  18 
  - 
  18 
  - 
Total finance lease cost
 $79 
 $- 
 $79 
 $- 
 
 
24
 
 
Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Three months ended June 30,
 
 
Six months ended June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
 Operating cash flows used in operating leases
 $138 
  170 
 $317 
 $332 
 Operating cash flows used in finance leases
  18 
  - 
  18 
  - 
 Financing cash flows used in finance leases
  702 
  - 
  702 
  - 
 
Supplemental non-cash flow information related to the operating ROU asset and lease liabilities was as follows for the three and six months ended June 30, 2020 and 2019:
 
 
 
Three months ended June 30,
 
 
Six months ended June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Operating leases
 
 
 
 
 
 
 
 
 
 
 
 
      Accretion of the lease liability
 $42 
 $36 
 $59 
 $76 
      Amortization of right-of-use assets
  142 
  146 
  302 
  287 
 
Weighted Average Remaining Lease Term
 
 
 
   Operating leases
 
7.3 years
 
   Finance leases
 
3.2 years
 
 
 
 
 
Weighted Average Discount Rate
 
 
 
 Operating leases
  13.8%
 Finance leases
  4.6%
 
Supplemental balance sheet information related to leases was as follows:
 
 
 
As of
 
 
 
June 30,
2020
 
 
December 31,
2019
 
Operating leases
 
 
 
 
 
 
Operating lease right-of-use assets
 $2,906 
 $557 
 
    
    
Current portion of operating lease liability
  223 
  377 
Long term operating lease liability
  2,730 
  200 
Total operating lease liabilities
  2,953 
  577 
 
    
    
Finance leases
    
    
Property and equipment, at cost
 $2,881 
 $- 
Accumulated depreciation
  (61)
  - 
 Property and equipment, net
  2,820 
  - 
 
    
    
Other current liability
  835 
  - 
Long term other liability
  1,308 
  - 
Total finance lease liabilities
  2,143 
  - 
 
 
25
 
 
Maturities of operating and finance lease liabilities were as follows:
 
Twelve months ended June 30,
 
Operating leases
 
 
Finance leases
 
 
 
 
 
 
 
 
2021
 $613 
 $914 
2022
  631 
  494 
2023
  565 
  494 
2024
  581 
  414 
2025
  599 
  - 
There after
  1,851 
  - 
Total lease payments
  4,840 
  2,316 
Less imputed interest
  (1,887)
  (173)
 
    
    
Total lease liability
 $2,953 
 $2,143 
 
Other Commitments
 
The Company entered into an agreement with Mitsubishi Chemical America, Inc. We purchased certain equipment to save energy used in the Keyes Plant. We also entered into a financing agreement with the seller for $5.7 million for this equipment. Payments pursuant to the financing transaction will commence after the installation date and interest will be charged based on the certain performance metrics after operation of the equipment. The equipment was delivered in March 2020; however the installation has been delayed due to the COVID-19 pandemic. Hence, we recorded the asset in construction in progress fixed assets and related liability in the short and long term debt of $0.5 million and $5.2 million, respectively as of June 30, 2020.
 
Property taxes
 
The Company entered into a payment plan with Stanislaus County for unpaid property taxes for the Keyes Plant site on June 28, 2018 by paying $1.5 million as a first payment. Under the annual payment plan, the Company was set to pay 20% of the outstanding redemption amount, in addition to the current year property taxes and any interest incurred on the unpaid balance to date annually, on or before April 10 starting in 2019. After making one payment, Company defaulted on the payment plan and as of June 30, 2020 and December 31, 2019, the balance in property tax accrual was $5.0 million and $4.1 million, respectively. Stanislaus County agreed not to enforce collection actions and we are now in discussions with Stanislaus County regarding a payment plan.
 
Legal Proceedings
 
On August 31, 2016, the Company filed a lawsuit in Santa Clara County Superior Court against defendant EdenIQ, Inc. (“EdenIQ”).  The lawsuit was based on EdenIQ’s wrongful termination of a merger agreement that would have effectuated the merger of EdenIQ into a new entity that would be primarily owned by Aemetis.  The lawsuit asserted that EdenIQ had fraudulently induced the Company into assisting EdenIQ to obtain EPA approval for a new technology that the Company would not have done but for the Company’s belief that the merger would occur.  The relief sought included EdenIQ’s specific performance of the merger, monetary damages, as well as punitive damages, attorneys’ fees, and costs.   In response to the lawsuit, EdenIQ filed a cross-complaint asserting causes of action relating to the Company’s alleged inability to consummate the merger, the Company’s interactions with EdenIQ’s business partners, and the Company’s use of EdenIQ’s name and trademark in association with publicity surrounding the merger.  Further, EdenIQ named Third Eye Capital Corporation (“TEC”) as a defendant in a second amended cross-complaint alleging that TEC had failed to disclose that its financial commitment to fund the merger included terms that were not disclosed. Finally, EdenIQ claimed that TEC and the Company concealed material information surrounding the financing of the merger.  By way of its cross-complaint, EdenIQ sought monetary damages, punitive damages, injunctive relief, attorneys’ fees and costs. In November 2018, the claims asserted by the Company were dismissed on summary judgment and the Company filed a motion to amend its claims, which remains pending. In December 2018, EdenIQ dismissed all of its claims prior to trial. In February 2019, the Company and EdenIQ each filed motions seeking reimbursement of attorney fees and costs associated with the litigation. On July 24, 2019, the court awarded EdenIQ a portion of the fees and costs it had sought in the amount of approximately $6.2 million. The Company recorded the $6.2 million as loss contingency on litigation during the year ended December 31, 2019. The Company’s ability to amend its claims and present its claims to the court or a jury could materially affect the court’s decision to award EdenIQ its fees and costs. In addition to further legal motions and a potential appeal of the Court’s summary judgment order, the Company plans to appeal the court’s award of EdenIQ’s fees and costs. The Company intends to continue to vigorously pursue its legal claims and defenses against EdenIQ.
 
 
26
 
 
6. Biogas LLC – Series A Preferred Financing
 
On December 20, 2018, Aemetis Biogas LLC entered into a Series A Preferred Unit Purchase Agreement (the “Preferred Unit Agreement”) by selling Series A Preferred Units to Protair-X Americas, Inc. (the “Purchaser”), with Third Eye Capital acting as an agent for the purchaser (the “Agent”). ABGL plans to construct and collect biogas from dairies located near the Keyes Plant. Biogas is a blend of methane along with CO2 and other impurities that can be captured from dairies, landfills and other sources. After a gas cleanup and compression process, biogas can be converted into bio-methane, which is a direct replacement of petroleum natural gas and can be transported in existing natural gas pipelines.
 
ABGL is authorized to issue 11,000,000 common units, and up to 6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued 6,000,000 common units to the Company. ABGL also issued 1,660,000 Series A Preferred Units to the Purchaser for $8,300,000 with the ability to issue an additional 4,340,000 Series A Preferred Units at $5.00 per Unit for a total of up to $30,000,000 in funding. Additionally, 5,000,000 common units are held in reserve as potential conversion units issuable to the Purchaser upon certain triggering events discussed below.
 
The Preferred Unit Agreement includes (i) preference payments of $0.50 per unit on the outstanding Series A Preferred Units commencing on the second anniversary, (ii) conversion rights for up to 1,200,000 common units or up to maximum number of 5,000,000 common units (also at a one Series A Preferred Unit to one common unit basis) if certain triggering events occur, (iv) one board seat of the three available to be elected by Series A Preferred Unit holders, (iii) mandatory redemption value at $15 per unit payable at an amount equal to 75% of free cash flow generated by ABGL, up to $90 million in the aggregate (if all units are issued), (iv) full redemption of the units on the sixth anniversary, (v) minimum cash flow requirements from each digester, and (vi) $0.9 million paid as fees to the Agent from the proceeds.
 
Triggering events occur upon ABGL’s failure to redeem units, comply with covenants, any other defaults or cross defaults, or to perform representations or warranties. Upon a triggering event: (i) the obligation of the Purchaser to purchase additional Series A Preferred Units is terminated, (ii) cash flow payments for redemption payments increases from 75% to 100% of free cash flows, and (iii) total number of common units into which preferred units may be converted increases from 1,200,000 common units to 5,000,000 common units on a one for one basis. As of June 30, 2020, ABGL has not completed construction within one year from the date of initial investment and generated minimum quarterly operating cash flows. Upon the violation of this covenant, cash flows applied for redemption payments increased to 100% from 75% of free cash flows.
 
From inception of the agreement to date, ABGL issued 3,200,000 Series A Preferred Units on first tranche for a value of $16.0 million and also issued 1,003,461 Series A Preferred Units on second tranche for a value of $5.0 million. The Company is accreting up these two tranches to the redemption value of $63.1 million over the estimated future cash flow periods of six years using the effective interest method. In addition, the Company identified freestanding future tranche rights and the accelerated redemption feature related to a change in control provision as derivatives which required bifurcation. These derivative features were assessed to have minimal value as of June 30, 2020 and December 31, 2019 based on the evaluation of the other conditions included in the agreement.
 
During the quarter ended June 30, 2020, ABGL issued 1,323,461 Series A Preferred Units for incremental proceeds of $6.6 million as part of the first and second tranches of the Preferred Unit Agreement. Consistent with the previous issuances, the units are treated as a liability as the conversion option was deemed to be non-substantive. The Company is accreting up to the redemption value of $19.9 million over the estimated future cash flow periods of six years from the original anniversary date using the effective interest method.
 
 
27
 
 
As of June 30, 2020 and December 31, 2019, the Company recorded Series A Preferred Unit liabilities of $24.3 million and $14.1 million net of unit issuance costs and inclusive of accretive preferences pursuant to this agreement.
 
7. Stock-Based Compensation
 
2019 Plan
 
On April 29, 2019, the Aemetis 2019 Stock Plan (the “2019 Stock Plan”) was approved by stockholders of the Company. This plan permits the grant of Incentive Stock Options, Non-Statutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units, Performance Shares and other stock or cash awards as the Administrator of the plan may determine in its discretion. The 2019 Stock Plan’s term is 10 years and supersedes all prior plans. The 2019 Stock Plan authorized the issuance of 200,000 shares of common stock for the 2019 calendar year, in addition to permitting the transfer and grant of any available and unissued or expired options under the prior Amended and Restated 2007 Stock Plan in an amount up to 177,246 options.
 
Employee grants have a general vesting term of 1/12th every three months and are exercisable at any time after vesting subject to continuation of employment. Option grants for directors have immediate vesting with a 10-year term expiration.
 
With the approval of the 2019 Stock Plan, the Zymetis 2006 Stock Plan and the Amended and Restated 2007 Stock Plan (the “Prior Plans,” and together with the 2019 Stock Plan, the “Stock Plans”) are terminated for granting any options under either plan. However, any options granted before the 2019 Stock Plan approved will remain outstanding and can be exercised, and any expired options issued pursuant to the Prior Plans can be granted under the 2019 Stock Plan.
 
On January 9, 2020, 771,500 stock option grants were issued for employees and directors under the 2019 Stock Plan. On March 28, 2020, 1,075,500 stock options grant were approved by Board for employees and directors under the 2019 Stock Plan.
 
On April 3, 2020, 450,000 stock option grants were issued for employees under the 2019 Stock Plan with 10 year term and immediate vesting.
 
On June 4, 2020, 10,000 stock option grant was approved by Board for a director under the 2019 Stock Plan with 10 year term and 2 year vesting.
 
As of June 30, 2020, 6.0 million options are outstanding under the Stock Plans.
 
Inducement Equity Plan Options
 
In March 2016, the Directors of the Company approved an Inducement Equity Plan (“Inducement Equity Plan,” together with the Stock Plans, the “Plans”) authorizing the issuance of 0.1 million non-statutory options to purchase common stock. As of June 30, 2020, no options are outstanding under the Inducement Equity Plan.
 
Common Stock Reserved for Issuance
 
The following is a summary of options granted under the Plans:
 
 
 
Shares Available for Grant
 
 
Number of Shares Outstanding
 
 
Weighted-Average Exercise Price
 
Balance as of December 31, 2019
  147 
  3,746 
 $1.38 
Authorized
  2,342 
  - 
  - 
Granted
  (2,307)
  2,307 
  0.69 
Exercised
  - 
  - 
  - 
Forfeited/expired
  25 
  (25)
  - 
 
    
    
    
Balance as of June 30, 2020
  207 
  6,028 
 $1.12 
 
 
28
 
 
As of June 30, 2020, there were 3.9 million options vested under all the Plans.
 
Stock-based compensation for employees
 
Stock-based compensation is accounted for in accordance with the provisions of ASC 718, Compensation-Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. We estimate the fair value of stock-based awards on the date of grant using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method.
 
For the three months ended June 30, 2020 and 2019, the Company recorded stock compensation expense in the amount of $325 thousand and $196 thousand, respectively. For the six months ended June 30, 2020 and 2019, the Company recorded stock compensation expense in the amount of $635 thousand and $486 thousand, respectively.
 
Valuation and Expense Information
 
All issuances of stock options or other issuances of equity instruments to employees as the consideration for services received by us are accounted for based on the fair value of the equity instrument issued. The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model for stock based compensation expense requires us to make assumptions and judgments about the variables used in the calculation, including the fair value of our common stock, the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. We also estimate forfeitures of unvested stock options. To the extent actual forfeitures differ from our estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. Compensation cost is recorded only for vested options. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment, and volatility is based on an average of the historical volatilities of the common stock of four entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants and the plan.
 
During the three months ended June 30, 2020 and 2019, 460,000 and 399,000 options were granted respectively. The weighted average fair value calculations for options granted during the three months ended June 30, 2020 and 2019 are based on the following assumptions:
 
Description
 
For the three months ended June 30,
 
 
 
2020
 
 
2019
 
Dividend-yield
  0%
  0%
Risk-free interest rate
  0.39%
  2.00%
Expected volatility
  87.09%
  88.58%
Expected life (years)
  5.02 
  6.81 
Market value per share on grant date
 $0.60 
 $0.92 
Fair value per share on grant date
 $0.41 
 $0.71 
 
 
29
 
 
As of June 30, 2020, the Company had $1.2 million of total unrecognized compensation expense for employees, which the Company will amortize over the 2.2 years weighted average remaining term.
 
8.          
Agreements
 
Working Capital Arrangement. Pursuant to a Corn Procurement and Working Capital Agreement with J.D. Heiskell, the Company agreed to procure whole yellow corn and grain sorghum, primarily from J.D. Heiskell. The Company has the ability to obtain grain from other sources subject to certain conditions; however, in the past all the Company’s grain purchases have been from J.D. Heiskell. Title and risk of loss of the corn pass to the Company when the corn is deposited into the Keyes Plant weigh bin. The term of the Corn Procurement and Working Capital Agreement expires on December 31, 2020 and the term can be automatically renewed for additional one-year terms. J.D. Heiskell further agrees to sell all WDG the Company produces to A.L. Gilbert. The Company markets and sells DCO to A.L. Gilbert and other third parties under the J.D. Heiskell Purchasing Agreement. The Company’s relationships with J.D. Heiskell, and A.L. Gilbert are well established and the Company believes that the relationships are beneficial to all parties involved in utilizing the distribution logistics, reaching out to widespread customer base, managing inventory, and building working capital relationships. These agreements are ordinary purchase and sale agency agreements for the Keyes Plant. On May 13, 2020, J.D. Heiskell and the Company entered into Amendment No.1 to the J.D. Heiskell Purchasing Agreement to remove J.D. Heiskell’s obligations to purchase ethanol from the Company under the J.D. Heiskell Purchasing Agreement.
 
The J.D. Heiskell’s sales activity associated with the Corn Procurement and Working Capital Agreement for the three and six months ended June 30, 2020 and 2019 are as follows:
 
 
 
 As of and for the three months ended June 30,
 
 
As of and for the six months ended June 30,
 
 
 
2020
 
 
2019
 
 
2020
 
 
2019
 
Ethanol sales
 $1,666 
  29,808 
 $26,049 
 $56,997 
Wet distiller's grains sales
  7,466 
  8,733 
  15,840 
  17,336 
Corn oil sales
  1,051 
  852 
  1,979 
  1,652 
Corn purchases
  22,541 
  30,719 
  51,755 
  59,980 
Accounts receivable
  55 
  1,238 
  55 
  1,238 
Accounts payable
  250 
  3,118 
  250 
  3,118 
 
Ethanol and Wet Distillers Grains Marketing Arrangement. The Company entered into an Ethanol Marketing Agreement with Kinergy and a Wet Distillers Grains Marketing Agreement with A.L. Gilbert. Under the terms of the agreements, subject to certain conditions, the Ethanol Marketing Agreement matures on August 31, 2020 and the Wet Distillers Grains Marketing Agreement matures on December 31, 2020 with automatic one-year renewals thereafter. For the three months ended June 30, 2020 and 2019, the Company expensed marketing costs of $0.5 million and $0.7 million respectively under the terms of both the Ethanol Marketing Agreement and the Wet Distillers Grains Marketing Agreement . For the six months ended June 30, 2020 and 2019, the Company expensed marketing costs of $1.1 million and $1.3 million, respectively.
 
9.          
Segment Information
 
Aemetis recognizes two reportable geographic segments: “North America” and “India.” The “North America” operating segment includes the Keyes Plant, the Riverbank Cellulosic Ethanol Facility, the Biogas Project, the Goodland Plant and the research and development facility in Minnesota.
 
The “India” operating segment includes the Kakinada Plant, the administrative offices in Hyderabad, India, and the holding companies in Nevada and Mauritius. The Company’s biodiesel is marketed and sold primarily to customers in India through brokers and by the Company directly.
 
 
30
 
 
Summarized financial information by reportable segment for the three and six months ended June 30, 2020 and 2019 follows:
 
 
 
Three months ended June 30, 2020
 
 
Three months ended June 30, 2019
 
 
 
North America
 
 
India
 
  Total Consolidated 
 
North America
 
 
India
 
 
Total Consolidated
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues
 $45,223 
  2,601 
  47,824 
 $39,486 
 $11,133 
 $50,619 
Cost of goods sold
  31,284 
  2,481 
  33,765 
  38,483 
  8,863